Cue Biopharma, Inc. business relationships
Companies named in Cue Biopharma, Inc.’s 10-K filed 2026-03-16, and public companies whose annual reports name Cue Biopharma, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 6% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Cue Biopharma, Inc.’s annual report 3
“We have financed our working capital requirements primarily through private and public offerings of equity securities, cash received from BI, IMSCP, LG Chem, Ono, and Merck Sharp & Dohme Corp. under collaboration agreements, and borrowings under the Loan Agreement.” SEC filing
“our plans to develop our drug product candidates, including our prioritization of our autoimmune programs, including CUE-401 and the CUE-500 series (excluding CUE-501, which has been licensed to Boehringer Ingelheim International GmbH);” SEC filing
“CUE-501, for which we entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BI) in April 2025, is being developed to target and deplete autoimmune disease-causing B cells, in patients with autoimmune disease caused by autoreactive, pathogenic B cells.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.